Vivalto Partners completed the acquisition of Linnea.

Vivalto Partners, a French private equity firm dedicated to healthcare, completed the acquisition of Linnea, a Swiss-based active pharma ingredients producer. Financial terms were not disclosed. This transaction marks a significant milestone for Vivalto Partners and represents a primary buyout, with a substantial investment from Linnea’s management team to support the company’s continued growth and innovation in the fast-expanding field of plant-based therapeutics and botanical ingredients.